The effect of immunization against OX-LDL with two different antigens in formation and development of atheroschlerosis among rabbits

Iranian Journal of Diabetes and Lipid Disorders

Volumn 6, Issue 4, 2007, Pages

  Asgari, Sedigheh ^a,b   Fattahi, Zahra ^a   Naderi, Gholam Ali ^a   Panah, Shirin Azam ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Sedigheh Tahereh Research Complex   (Iran)

Author keywords

Anti OX LDL antibody; Atherosclerosis; Cu LDL; Fatty streak; Immune system; MDA LDL

Indexed keywords

ANTIGEN; CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ATHEROSCLEROSIS; CHEMICAL ANALYSIS; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY; DIET RESTRICTION; IMMUNE SYSTEM; IMMUNIZATION; LEFT CORONARY ARTERY; NONHUMAN; RABBIT;

EID: 37249025577     PISSN: 17267544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. G.K Hansson, P. Libby, U. Schonbeck and Z.Q Yan, innate and adaptive immunity in the pathogenesis of atherosclerosis Cric Res 2002;91:281-291.
3. Wick G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16:27-33.
4. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
5. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross- regulatory roles of immunity and autoimmunity in atherosclerosis. Immunol Res 1996;15:315-22.
6. Ross, R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-126.
7. Johannes H. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clinica chimica Acta 2004;348:1-8.
8. Yaniv Sherer, Yehuda shoenfeld Immunomodulation for treatment and prevention of atherosclerosis. Auto immunity Reviews 2002;1:21-27.
9. Arnon Afek, Jacob George, Boris Gilburd, Lubica Rauova, Iris Goldberg, Juri Kopolovic. Immunization of low density lipoprotein receptor deficient (LDL-RD) mice with heart shook protein 65 (HSP-65) promotes Early atherosclerosis. J autoimmunity 2000;14:115-127.
10. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, et al. Cloning o∼JnOnoclonal autoantibodies to epitopes of oxidized lipoproteitis from apolipoprotein E-defi- cient mice. Demonstration of epitopes of oxidized low density k lipoprotein in human plasma. J Clin Invest 1996;98:800-14.
11. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner OC′ ISocher SS, Butler SW, et aI. Low density lipoprotein under- goes oxidative modification in vivo. Proc Natl Acad Sci 1989;86:1372-6.
12. Yla-Herttuaia S, Palinski W, Butler SW, Picard S, Steinberg D, IWitztum JL. Rabbit and human atherosclerotic lesions contain . IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
13. M.E Rosen feld, W. Palinski, S. Yla Herttuala, S.Bulter and Jl. Witztum Distribution of oxidation specific lipid protein adducts and apolipoprotein B in atherosclerosis lesion of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336-349.
14. J.T. Salonen, S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyssonen, W. Palinski and J.L. Witztum, Autoantibody against oxidised LDL and , progression of carotid atherosclerosis, Lancet 1992;339:883-887.
15. C.Bergmark, R. Wu, U. de faire. A.K. Lefuert and J. SW edenborg. Patients with early-onset peripheral vascular disease have increased levels of auto antibodies against oxidized LDL. Arteriovas thromb Vasc Biol 1995;15: 441-445.
16. J. Hulthe, L. Bokemark and B. Fagerberg. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58 year old subjectively clinically healthy men. Anterioscler Thromb Vas Biol 2001;21: 101-107.
17. M.N. Bui, M.N. Sack, G. Moutsatsos, D.Y.Lu P. Autoantibody titers to oxidized LDL in patients with coronary atherosclerosis. Am Heart J 1996;131: 663-667.
18. J. Halthe, J. Wikstrand, H. Emanuelsson, O. Wiklund, P.J.de Fegter and I. Wendelhag Atherosclerotic change in the carotid artery bulb as measured by B-made ultrasound are associated with the extent of coronary atherosclerosis. Strok 1997;28: 1189-1194.
19. J Hulthe, Owikluad E. Hurt-camejo and G. Bondjers, Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules and phospholipase A(2). Artherioscler Thromb Vas Biol 2001;21:262-274.
20. Tetso shoji, Yoshiki Nishizawa, Mariko Fukumoto, Kyoko Shimamura. Inverse relationship between circulation oxidized low density lipoprotein (OX-LDL) and anti-OX-LDL antibody levels in healthy subjects. Atherosclerosis 2000;148: 171-177.
21. Stemme S, Faber B, Holm J, Wlklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci 1995;92:3893-7.
22. Lopes Virella M, Koshinen S, Mironova M, Horne D, Klein R, Chasserean C, Enockson C, Vivella G. The preparation of copper-oxidized LDL for measurement of oxidized LDL antibodies by EIA. Atherosclerosis 2000;152:07-115.
23. Steinbrech UP, Oxidation of human low density lipoprotein result in derivatization of lysine residues of (APoB) by lipid proxide decomposition products. J Biol Chem 1987;262: 36.3-8.
24. Harberland ME, Fogelman A.M, Edwards S.P. Specificity of receptor-mediated recognition of malondialdehyde modified low density lipoproteins. Proos Natl Acade Sci 1981;79: 1712-1716.
25. W. Palinski, E. Miller, J.L. Witztum, Immunization of low density lipoprotein (LDL) receptor-deficient habbits with homologous malondialdehyde modified LDL atherogenesis. Proc Natl Acad Sci 1995;92:821-825.
26. Fischer Hansen BA, Mortensen JF, Hansen P, Ibsen H, Frandsen. 1994. Atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Evaluation by microscopic and biochemical methods and comparison of atherosclerosis variables. APMIS 102: 177-190.
27. S. Ameli, A Hultgardh-Nilsson, J. Regnstrom,F. Calara, J. Yano, B. Cercek, P.K. Shah, J. Nilsson, Effect of immunization with homologous LDL, and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasco Bioi 1996;16: 1074-1079.
28. S. Freigang, S. Horkko, E. Miller, J.L. Witztum, W. Palinski, Immunization of LDL receptor-deficient mice with homologous malondialdehydOomodilied and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasco Bioi 1998;18:1972-1982.
29. J. George, A. Mek, B. Gilburd, H. Levkovitz, A. Shaish, I. Goldberg, -Y. Kopolovic, G. Wick, Y. Shoenfeld, D. Harats, Hyperimmunization of apo-E-deficient mice with homologoUl malondialdehyde low- density lipoprotein suppress:s early atherogenesis. Atherosclerosis 1998; 138: 147-152.
30. G. Virella, I. Virella, R.B. Leman, M.B. Pryor and M.F. Lopes-Virella, Anti-oxidized low- density lipoprotein antibodies in patients wi∼th coronary heart disease and normal healthy volunteers. Int. J: Clin Lab Res 1993;23: 95-101.
31. Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57 BL/6 mice treated with cyclosporine A. Am J Pathol 1993;142:1906-15.
32. Nicoletti A, Caligiuri G, Hansson GK. Immunomodulation of atherosclerosis: myth and reality. J Intern Med 2000;247:397-405.
33. Usitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, uramaa R, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-ile- pendent diabetes mellitus. Arterioscler Thromb Vasc Bioi 1996; 16: 1236-42.
34. P.M.Riker, N. Rifai, L. Ross, JE. Buring and N.R. Cook. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med 2002;347: 1557-1565.
35. J. Khallou-Laschet. Et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mic. Atherosclerosis 2000; 184: 330-341.
36. Peter Riis Hansen, et al. Freunds adjuvant alon is antiatherogenic in apo-E-deficient mice and specific immunization against TNF-X coners no additional benefit. Atherosclerosis 2001;158: 87-94.
37. S. Freigang, S. Horkko, E. Miller, J.L. Witztum, W. Palinski, Immunization of LDL receptor-deficient mice with homologous malondialdehyde modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasco Bioi 1998;18: 1972-1982.
38. J. George, A. Mek, B. Gilburd, H. Levkovitz, A. Shaish, I. Goldberg, -Y. Kopolovic, G. Wick, Y. Shoenfeld, D. Harats, Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low- density lipoprotein suppress early atherogenesis, Atherosclerosis 1998; 138: 147-152.
39. G. Virella, I. Virella, R.B. Leman, M.B. Pryor and M.F. Lopes-Virella, Anti-oxidized low- density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-101.
40. M.I-.J.Uusitupa,L.Niskanen, J.Luoma, P. Vilja, M..Mercuri, R. Rauramaa et al, Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non- insulin-dependent diabetes mellitus. Arterioscler Thromb Vasco Biol 1996; 16: 1236-1242.